ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,858.89
      -0.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC
      6. PharmaTher Holdings Ltd (QB) (PHRRF)

      7. PharmaTher Holdings Ltd (QB) (PHRRF) News

      PHRRF

      PharmaTher (QB) (PHRRF)

      PharmaTher Holdings Ltd (QB)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:USOTC:PHRRF
      DateTimeSourceHeadlineSymbolCompany
      09/19/20226:31AMTipRanksAnalysts Offer Insights on Healthcare Companies: PharmaTher Holdings Ltd (OtherPHRRF), Rezolute (RZLT) and ADC Therapeutics (ADCT)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
      06/15/20225:03AMTipRanksH.C. Wainwright Keeps a Buy Rating on PharmaTher Holdings Ltd (PHRRF)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
      11/22/20216:16AMTipRanksH.C. Wainwright Thinks NPharmaTher’s Stock is Going to RecoverUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      11/11/202110:00AMInvestorsHub NewsWirePharmaTher Announces Positive Research Results for Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      11/03/20218:03AMInvestorsHub NewsWirePharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      10/19/20217:07AMInvestorsHub NewsWirePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine ProductsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      10/13/20219:20AMInvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain SyndromeUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      09/21/202110:19AMInvestorsHub NewsWirePharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded FundUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      09/13/20219:03AMInvestorsHub NewsWirePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022USOTC:PHRRFPharmaTher Holdings Ltd (QB)
      08/04/20218:15AMInvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral SclerosisUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      07/21/20218:19AMInvestorsHub NewsWirePharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      06/16/202111:14AMInvestorsHub NewsWirePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat DepressionUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      05/25/20218:45AMInvestorsHub NewsWirePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      05/17/20218:02AMInvestorsHub NewsWirePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      04/27/20217:47AMInvestorsHub NewsWirePharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      04/20/20218:00AMInvestorsHub NewsWirePharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical TrialUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      04/15/202111:32AMInvestorsHub NewsWirePharmaTher Provides Update on Psychedelic Product ProgramsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      03/02/20217:34AMInvestorsHub NewsWirePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      02/17/202110:11AMInvestorsHub NewsWirePharmaTher Announces Sale of Psilocybin ProgramUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      02/04/20218:21AMInvestorsHub NewsWirePharmaTher Announces Successful Completion of Pre-IND Meeting with FDAUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      02/01/20218:19AMInvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver KetamineUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
      01/19/20218:07AMInvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
       Showing the most relevant articles for your search:USOTC:PHRRF